免疫检查点抑制剂治疗晚期肝细胞癌患者研究进展*

doi:10.3969/j.issn.1672-5069.2023.03.039

摘要/Abstract

摘要： 免疫检查点抑制剂是一种癌症免疫治疗药物,通过改善肿瘤周围免疫微环境而达到抗肿瘤目的。肝细胞癌是最常见的原发性肝癌类型,疾病晚期的治疗效果差。免疫检查点抑制剂治疗晚期肝细胞癌具有一定的疗效。本文对免疫检查点抑制剂在晚期肝细胞癌应用的作用机制、治疗进展和不良事件作一综述。

关键词: 肝细胞癌, 免疫检查点抑制剂, 治疗, 不良事件

Abstract: Immune checkpoint inhibitor is a kind of cancer immunotherapy agents, which has anti-tumor activities by improving immune microenvironment around the tumors. The hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the treatment efficacy of advanced disease is poor. The immune checkpoint inhibitors have a certain effects on advanced HCC. In this article, we will review the mechanism, treatment and adverse events of immune checkpoint inhibitors in treating patients with advanced HCC.

Key words: Hepatocellular carcinoma, Immune checkpoint inhibitors, Therapy, Adverse events

陈鹏, 刘欢, 徐亮. 免疫检查点抑制剂治疗晚期肝细胞癌患者研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 453-456.

Chen Peng, Liu Huan, Xu Liang. Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2023, 26(3): 453-456.

参考文献

[1] Brar G, Greten T.F, Graubard B.I, et al. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis.Hepatol Commun, 2020, 4:1541-1551.
[2] Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer treat Rev, 2019,77:20-28.
[3] Saffo S, Taddei TH. Systemic management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digest Dis Sci, 2019,64 (4):1016-1029.
[4] Collier JL, Weiss SA, Pauken KE, et al. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol, 2021, 22(7):809-819.
[5] Huyen PTM, Dung DTN, Weiß PJ, et al. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression. Int J Infect Dis, 2022,115:229-236.
[6] Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4. Adv Exp Med Biol, 2020,1248:7-32.
[7] Gomez S, Tabernacki T, Kobyra J, et al. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol, 2020, 65:99-113.
[8] Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res, 2018, 48:597-607.
[9] Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther, 2018, 18(12): 1169-1175.
[10] Yau T,Park J.W,Finn R.S,et al. LBA38_PR-CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann. Oncol, 2019, 30: v874-v875.
[11] Lim Chiew Woon, Lee Joycelyn Jie Xin, Choo Su Pin, et al. Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther, 2020,20(7):687-693.
[12] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):a non-randomised,open-label phase 2 trial. Lancet Oncol, 2018,19 (7):940-952.
[13] Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol, 2020,38(3):193-202.
[14] Feun LG, Li YY, Wu C, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer, 2019, 125(20):3603-3614.
[15] Yu R, Wang W, Li T, et al. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. Future Oncol, 2021, 17(31):4081-4089.
[16] Jinzhang Chen, Xiaoyun Hu, Qi Li, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med, 2020,8(18):1187.
[17] Maestri M, Pallozzi M, Santopaolo F, et al. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opin Investig Drugs, 2022,31(4):347-360.
[18] Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol, 2013,59:81-88.
[19] Silva IP, Long GV. Systemic therapy in advanced melanoma: Integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol, 2017, 29:484-492.
[20] Zhou G, Sprengers D, Boor PPC, et al. Anti-bodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells inhepatocellular carcinomas. Gastroenterology, 2017,153:1107-1119.e10.
[21] Thomas Yau, Yoon-Koo Kang, Tae-You Kim, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol, 2020,6(11):e204564.
[22] Kevin Wright. FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC. Oncology (Williston Park), 2020,34(4):693606.
[23] Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer, 2021,9(2):e001945.
[24] Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol, 2017,35(15_suppl):4073.
[25] Kelley RK, Sangro B, Harris WP, et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). J Clin Oncol, 2020, 38(suppl):4508.
[26] Finn RS, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020,382(20):1894-1905.
[27] Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer, 2020, 137:272-284.
[28] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol, 2020, 38(26): 2970.
[29] Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res, 2021, 27(4):1003-1011.
[30] Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J. Gastroenterol, 2019, 25:789-807.
[31] El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer, 2019, 125(19):3312-3319.
[32] Ahmed Montasser, Aurélie Beaufrère, François Cauchy, et al. Transarterial chemoembolization enhances programmed death 1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology, 2021, 79(1):36-46.
[33] Zheng L, Fang S, Wu F, et al. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci, 2021,7:609322.
[34] Xu ZN, Huang JJ, Zhou J, et al. Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy. Zhonghua Nei Ke Za Zhi, 2021, 60(7):630-636.
[35] Chao J, Zhu Q, Chen D, et al. Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Front Oncol, 2021,11:667555.

免疫检查点抑制剂治疗晚期肝细胞癌患者研究进展^*

Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张绍全, 林炳亮. 肠道菌群与肝硬化研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 313-316.
[2]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[3]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[4]	王云云, 吴万锋, 李黎. 直接抗病毒药物治疗基因1b型慢性丙型肝炎合并2型糖尿病患者疗效及对血糖控制的影响^*[J]. 实用肝脏病杂志, 2023, 26(3): 344-347.
[5]	许海苗, 郑瑞琦, 丁惠国. 匹伐他汀联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 352-355.
[6]	郭银燕, 岳枝, 盖晓冬, 冯艳红, 张杰东. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征患者临床和肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 372-375.
[7]	何学元, 马建勋, 杨屹立, 张敏, 潘新民. 布地奈德治疗熊去氧胆酸治疗不应答的原发性胆汁性胆管炎患者疗效及血清氧化应激指标的变化^*[J]. 实用肝脏病杂志, 2023, 26(3): 376-379.
[8]	王俊红, 戴玲, 陈国斌, 杨路平, 周晶. 还原型谷胱甘肽、甘草酸二铵和复方甘草酸苷治疗抗结核药物所致药物性肝损伤患者成本-效益分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 380-383.
[9]	卫栋萍, 韩黎黎, 凌佳慧, 顾晓琴, 曹永峰. 甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 388-391.
[10]	叶丝陶, 黄晓铨, 陈世耀. 血浆纤维蛋白原水平预测乙型肝炎肝硬化患者内镜治疗后食管胃静脉曲张再出血风险效能分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 392-395.
[11]	刘坤, 徐菁, 马竹芳. 托伐普坦联合腹水超滤浓缩回输术治疗肝硬化并发顽固性腹水患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 396-399.
[12]	陈启全, 李晓婷, 杨勋祎, 王翔. 超声造影、剪切波弹性成像和增强CT检查诊断肝细胞癌价值分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 408-411.
[13]	唐亮, 陈曦, 王文高, 董超. TACE联合直线加速器三维适形放疗治疗中晚期原发性肝癌患者近期临床疗效研究[J]. 实用肝脏病杂志, 2023, 26(3): 416-419.
[14]	张威, 陈国林, 王航, 余良, 孔祥璐. 合并不同基础疾病的细菌性肝脓肿患者临床特征分析[J]. 实用肝脏病杂志, 2023, 26(3): 424-427.
[15]	张琼, 陈士颖, 夏维. 超声引导下无水乙醇与聚桂醇硬化治疗单纯性肝囊肿患者效果比较研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 428-431.